RT Journal Article
T1 Longitudinal Assessment of Tau-Associated Pathology by 18F-THK5351 PET Imaging: A Histological, Biochemical, and Behavioral Study
A1 Moreno-Gonzalez, Ines
A1 Edwards III, George A.
A1 Hasan, Omar
A1 Gamez, Nazaret
A1 Schulz, Jonathan E.
A1 Fernandez-Valenzuela, Juan Jose
A1 Gutierrez, Antonia
A1 Soto, Claudio
A1 Schulz, Paul E.
K1 PET imaging
K1 Tau
K1 THK5351
K1 Tracer
K1 Biomarker
K1 Histological assessment
K1 Cognitive impairment
K1 Tauopathy
K1 Alzheimer’s disease
K1 Dementia
K1 Tomografía por emisión de positrones
K1 Proteínas tau
K1 Trazadores radiactivos
K1 Biomarcadores
K1 Técnicas histológicas
K1 Disfunción cognitiva
K1 Tauopatías
K1 Enfermedad de Alzheimer
K1 Demencia
AB Several common and debilitating neurodegenerative disorders are characterized by the intracellular accumulation of neurofibrillary tangles (NFTs), which are composed of hyperphosphorylated tau protein. In Alzheimer's disease (AD), NFTs are accompanied by extracellular amyloid-beta (Aβ), but primary tauopathy disorders are marked by the accumulation of tau protein alone, including forms of frontotemporal dementia (FTD), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP), among others. 18F-THK5351 has been reported to bind pathological tau as well as associated reactive astrogliosis. The goal of this study was to validate the ability of the PET tracer 18F-THK5351 to detect early changes in tau-related pathology and its relation to other pathological hallmarks. We demonstrated elevated in vivo 18F-THK5351 PET signaling over time in transgenic P301S tau mice from 8 months that had a positive correlation with histological and biochemical tau changes, as well as motor, memory, and learning impairment. This study indicates that 18F-THK5351 may help fill a critical need to develop PET imaging tracers that detect aberrant tau aggregation and related neuropathology in order to diagnose the onset of tauopathies, gain insights into their underlying pathophysiologies, and to have a reliable biomarker to follow during treatment trials.
PB MDPI
YR 2021
FD 2021-10-12
LK http://hdl.handle.net/10668/4483
UL http://hdl.handle.net/10668/4483
LA en
NO Moreno-Gonzalez I, Edwards GA III, Hasan O, Gamez N, Schulz JE, Fernandez-Valenzuela JJ, et al. Longitudinal Assessment of Tau-Associated Pathology by 18F-THK5351 PET Imaging: A Histological, Biochemical, and Behavioral Study. Diagnostics. 2021 Oct 12;11(10):1874
DS RISalud
RD Apr 17, 2025